Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reducti... ( FORT LAUDERDALE Fla. Dec. 10 /- Synov...)

Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt

Date:12/10/2008

FORT LAUDERDALE, Fla., Dec. 10 /PRNewswire-FirstCall/ -- Synovics Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a specialty pharmaceutical company, today announced a further reduction of its debt by paying off the last remaining $780,000 of the "Kirk 2008 Bridge Loan" through the sale of additional Series C Convertible Redeemable Preferred Stock ("Series C Preferred Stock") in that amount.

As previously reported in the Current Report on Form 8-K dated May 15, 2008, the Company completed an initial closing on May 9, 2008 of its Series C Preferred Stock offering (the "Series C Offering"). On August 21, and September 25, 2008 the Company completed additional closings of its Series C Offering whereby, in consideration for a total additional investment of $1.78 million, Synovics sold to Svizera Holdings BV ("Svizera"), an affiliate of Maneesh Pharmaceuticals, Ltd., a total of 3,560 shares of Series C Preferred Stock, convertible into 3,560,000 shares of common stock, together with warrants to acquire up to an additional 1,780,000 shares of common stock. Svizera (and Maneesh) have invested a total of $14,080,000 as equity in Synovics.

The cash received was used to further reduce the Company's short and long term debt. Total Company debt owed on May 9, 2008 including accrued interest was $20,640,683. Capital provided by investors to Synovics this year, including funds in the latest tranche of the Series C Offering, has allowed the Company to reduce or pay off debt, including satisfying the "Kirk 2008 Bridge Loan" arranged through Axiom Capital Management. As shown in the table below, the current reduced outstanding debt (principal and accrued interest) owed by the Company is $6,190,000, of which $5,650,000 is indebtedness under the Company's credit facility with Bank of India.


                               October 15, 2008     May 9, 2008
    2005 Bridge Notes                        $0      $4,036
'/>"/>
SOURCE  Synovics Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved 
0

GOOD

Page: 1 2 3 4 5 
Related medicine news :

1. Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer
2. Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract
3. Synovics Pharmaceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC
4. Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
5. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas

Post Your Comments:

Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reducti...( FORT LAUDERDALE Fla. Dec. 10 /- Synov...),Health